BioCentury
ARTICLE | Financial News

ImmunoMet raises $5.2M in series A

March 9, 2016 2:27 AM UTC

ImmunoMet Therapeutics (Houston, Texas) raised $5.2 million in a series A round led by Mirae Asset Venture Investments. Aju Tech, GNTech and MetaVest also participated.

Next half, ImmunoMet expects to begin a Phase I study of oxidative phosphorylation inhibitor IM156 to treat glioblastoma. CSO Sanghee Yoo told BioCentury the company is also developing undisclosed candidates in immuno-oncology. ...